Ostrum Asset Management Sells 582 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Ostrum Asset Management decreased its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 5.4% during the fourth quarter, Holdings Channel reports. The fund owned 10,167 shares of the medical equipment provider’s stock after selling 582 shares during the period. Ostrum Asset Management’s holdings in Intuitive Surgical were worth $5,307,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in ISRG. Atala Financial Inc bought a new position in Intuitive Surgical in the fourth quarter worth $25,000. Berbice Capital Management LLC bought a new position in shares of Intuitive Surgical in the 4th quarter worth about $26,000. BankPlus Trust Department bought a new position in shares of Intuitive Surgical in the 4th quarter worth about $28,000. Hurley Capital LLC purchased a new position in Intuitive Surgical during the 4th quarter valued at about $28,000. Finally, Summit Securities Group LLC bought a new stake in Intuitive Surgical during the fourth quarter worth about $30,000. Institutional investors own 83.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ISRG. Truist Financial decreased their target price on shares of Intuitive Surgical from $666.00 to $605.00 and set a “buy” rating for the company in a research note on Monday, March 17th. Barclays raised their price objective on Intuitive Surgical from $610.00 to $674.00 in a research report on Monday, January 27th. Royal Bank of Canada boosted their target price on Intuitive Surgical from $611.00 to $641.00 in a report on Monday, January 27th. Jefferies Financial Group raised their price target on Intuitive Surgical from $475.00 to $575.00 in a report on Monday, January 27th. Finally, Raymond James lifted their price target on Intuitive Surgical from $560.00 to $688.00 and gave the stock an “outperform” rating in a research report on Friday, January 24th. One analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, Intuitive Surgical presently has an average rating of “Moderate Buy” and an average price target of $611.81.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, CFO Jamie Samath sold 269 shares of the business’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $590.00, for a total transaction of $158,710.00. Following the completion of the sale, the chief financial officer now owns 3,282 shares of the company’s stock, valued at approximately $1,936,380. The trade was a 7.58 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Amal M. Johnson sold 4,635 shares of the company’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $566.60, for a total value of $2,626,191.00. Following the completion of the sale, the director now owns 12,275 shares of the company’s stock, valued at approximately $6,955,015. The trade was a 27.41 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 33,754 shares of company stock valued at $17,691,621. Insiders own 0.70% of the company’s stock.

Intuitive Surgical Stock Up 0.3 %

NASDAQ ISRG opened at $482.74 on Monday. The company has a 50-day moving average price of $522.23 and a 200-day moving average price of $532.71. Intuitive Surgical, Inc. has a 52 week low of $364.31 and a 52 week high of $616.00. The firm has a market capitalization of $171.94 billion, a P/E ratio of 75.31, a PEG ratio of 5.85 and a beta of 1.55.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.